The rising popularity in GLP-1 agonists for diabetes has led to a question about delivery routes : transdermal systems versus tablets . Traditionally , GLP-1 drugs were solely available in oral form, but the emergence of transdermal delivery presents a alternative option . Transdermal systems might suit individuals with challenges with oral medicat